Director, Contract Optimization and Strategy Team (COST)

Job description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The COST-Vendor Director leads the end-to-end outsourcing of one or more indications and supports governance of external service providers for current and future clinical trials for multiple Development functions, with a strong emphasis on Clinical Vendors (e.g., CRO’s, imaging, cardiac, IRT, data management, Pharmacovigilance, etc.) Responsibilities include partnering with the clinical operations and other functional t...